Breast cancer is one of the most common cancers in Malaysia. Recently, a new nomenclature was introduced for breast cancers with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 1+, or 2+ with negative in situ hybridization (ISH), i.e., HER2-low breast cancer. In current clinical practice, these breast cancers are reported as HER2-negative. Clinical trials have shown that HER2-low breast cancer benefits from targeted therapy with anti-HER2 antibody-drug conjugates. Unfortunately, various challenges and obstacles are faced by local pathologists in HER2 testing, which may jeopardize the standard of care for patients with HER2-low breast cancer. This consensus guideline aims to elucidate standard practices pertaining to HER2 testing and HER2-low interpretation in Malaysia. Topics discussed among a panel of local experts include tissue sampling and handling, assay and antibody selection, result interpretation and reporting, and quality assurance. Practice recommendations made in this consensus guideline reflect current international guidelines and, where appropriate, adapted to the Malaysian landscape.

1. Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & colleagues. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast, 66, 15–23.
2. Malaysia National Cancer Registry. (2020). Summary of Malaysia National Cancer 2012–2016. Ministry of Health Malaysia. https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/2012-2016%20(MNCRR)/Summary_MNCR_2012-2016_-_06112020.pdf
3. Ministry of Health Malaysia. (2018). Malaysian study on cancer survival. https://www.moh.gov.my/moh/resources/Penerbitan/Laporan/Umum/Malaysian_Study_on_Cancer_Survival_MySCan_2018.pdf
4. Gutierrez, C., & Schiff, R. (2011). HER2: Biology, detection, and clinical implications. Archives of Pathology & Laboratory Medicine, 135(1), 55–62.
5. Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., & colleagues. (2018). Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Journal of Clinical Oncology, 36(20), 2105–2122.
6. Subramaniam, S., Bhoo-Pathy, N., Taib, N. A., Tan, G. H., See, M. H., Jamaris, S., Ho, G. F., Looi, L. M., & Yip, C. H. (2015). Breast cancer outcomes as defined by the estrogen receptor, progesterone receptor, and human growth factor receptor-2 in a multi-ethnic Asian country. World Journal of Surgery, 39(10), 2450–2458.
7. Devi, C. R., Tang, T. S., & Corbex, M. (2012). Incidence and risk factors for breast cancer subtypes in three distinct South-East Asian ethnic groups: Chinese, Malay and natives of Sarawak, Malaysia. International Journal of Cancer, 131(12), 2869–2877.
8. Pan, J. W., Zabidi, M. M. A., Ng, P. S., Meng, M. Y., Hasan, S. N., Sandey, B., Sammut, S. J., Yip, C. H., Rajadurai, P., Rueda, O. M., & colleagues. (2020). The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. Nature Communications, 11, Article 6433.
9. Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018). Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiology, Biomarkers & Prevention, 27(6), 619–626.
10. Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., & D’Amico, R. (2012). Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews, 2012(4), Article CD006243.
11. Ishii, K., Morii, N., & Yamashiro, H. (2019). Pertuzumab in the treatment of HER2-positive breast cancer: An evidence-based review of its safety, efficacy, and place in therapy. Core Evidence, 14, 51–70.
12. Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., & colleagues. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New England Journal of Medicine, 355(26), 2733–2743.
13. Krop, I. E., Kim, S. B., Martin, A. G., LoRusso, P. M., Ferrero, J. M., Badovinac-Crnjevic, T., Hoersch, S., Smitt, M., & Wildiers, H. (2017). Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. The Lancet Oncology, 18(6), 743–754.
14. Schettini, F., Chic, N., Brasó-Maristany, F., Paré, L., Pascual, T., Conte, B., Martínez-Sáez, O., Adamo, B., Vidal, M., Barnadas, E., & colleagues. (2021). Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer, 7, Article 1.
15. Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., & colleagues. (2020). HER2-low breast cancer: Pathological and clinical landscape. Journal of Clinical Oncology, 38(17), 1951–1962.
16. Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., & colleagues. (2022). Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. New England Journal of Medicine, 387(1), 9–20.
17. The ASCO Post. (2022). FDA approves first targeted therapy for HER2-low breast cancer. https://ascopost.com/issues/september-10-2022/fda-approves-first-targeted-therapy-for-her2-low-breast-cancer/
18. Sakach, E., Sacks, R., & Kalinsky, K. (2022). Trop-2 as a therapeutic target in breast cancer. Cancers, 14(23), Article 5936.
19. U.S. Food and Drug Administration. (2021). FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer
20. U.S. Food and Drug Administration. (2023). FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-hr-positive-breast-cancer
21. U.S. Food and Drug Administration. (2023). TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use [Prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf
22. Rugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., Tredan, O., Ciruelos, E. M., Dalenc, F., Gomez Pardo, P., & colleagues. (2022). LBA76 overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Annals of Oncology, 33(Suppl 7), S1386.
23. ClinicalTrials.gov. (2019). Study of DS-8201a, an antibody drug conjugate for advanced breast cancer patients, with biomarkers analysis (DAISY) (ClinicalTrials.gov Identifier NCT04132960). https://clinicaltrials.gov/ct2/show/NCT04132960
24. Diéras, V., Deluche, E., Lusque, A., Pistilli, B., Bachelot, T., Pierga, J. Y., Viret, F., Levy, C., Salabert, L., Du, F. L., & colleagues. (2022). Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY). Cancer Research, 82(4_Supplement), Article PD8-02.
25. ClinicalTrials.gov. (2020). Study of trastuzumab deruxtecan (T-DXd) vs. investigator’s choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer (DB-06) (ClinicalTrials.gov Identifier NCT04494425). https://clinicaltrials.gov/ct2/show/NCT04494425
26. ClinicalTrials.gov. (2020). A phase 1b study of T-DXd combinations in HER2-low advanced or metastatic breast cancer (DB-08) (ClinicalTrials.gov Identifier NCT04556773). https://clinicaltrials.gov/ct2/show/NCT04556773
27. ClinicalTrials.gov. (2013). Phase 2 study of the monoclonal antibody MGAH22 (margetuximab) in patients with relapsed or refractory advanced breast cancer (ClinicalTrials.gov Identifier NCT01828021). https://clinicaltrials.gov/ct2/show/NCT01828021
28. Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., & colleagues. (2019). Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study. The Lancet Oncology, 20(8), 1124–1135.
29. Wang, J., Liu, Y., Zhang, Q., Feng, J., Fang, J., Chen, X., Han, Y., Li, Q., Zhang, P., Yuan, P., & colleagues. (2021). RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. Journal of Clinical Oncology, 39(15_suppl), 1022.
30. Li, J., Guo, Y., Xue, J. L., Peng, W., Ge, X. X., Zhao, W., Dai, C. Q., Xue, L. Q., Tang, W. B., & Hu, C. H. (2020). First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed/refractory solid tumors. Journal of Clinical Oncology, 38(15_suppl), TPS1101.
31. Wolff, A. C., Somerfield, M. R., Dowsett, M., Hammond, M. E. H., Hayes, D. F., McShane, L. M., Saphner, T. J., Spears, P. A., & Allison, K. H. (2023). Human epidermal growth factor receptor 2 testing in breast cancer: ASCO–College of American Pathologists guideline update. Journal of Clinical Oncology, 41(22), 3867–3872.
32. Md Pauzi, S. H., Masir, N., Yahaya, A., Mohammed, F., Tizen Laim, N. M. S., Mustangin, M., Aizudin, A. N., Talib, A., Teoh, K. H., Karim, N., & colleagues. (2021). HER2 testing by immunohistochemistry in breast cancer: A multicenter proficiency ring study. Indian Journal of Pathology and Microbiology, 64(4), 677–682.
33. Ministry of Health Malaysia. (n.d.). HER2 testing. https://www.moh.gov.my/index.php/database_stores/attach_download/347/115
34. Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., & colleagues. (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Archives of Pathology & Laboratory Medicine, 138(2), 241–256.
35. Mitra, S., & Dey, P. (2016). Fine-needle aspiration and core biopsy in the diagnosis of breast lesions: A comparison and review of the literature. CytoJournal, 13, Article 18.
36. Li, H. N., & Chen, C. H. (2019). Ultrasound-guided core needle biopsies of breast invasive carcinoma: When one core is sufficient for pathologic diagnosis and assessment of hormone receptor and HER2 status. Diagnostics, 9(2), Article 54.
37. Kim, S. W., Roh, J., & Park, C. S. (2016). Immunohistochemistry for pathologists: Protocols, pitfalls, and tips. Journal of Pathology and Translational Medicine, 50(6), 411–418.
38. Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., & colleagues. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Archives of Pathology & Laboratory Medicine, 131(1), 18–43.
39. Li, X., Deavers, M. T., Guo, M., Liu, P., Gong, Y., Albarracin, C. T., Middleton, L. P., & Huo, L. (2013). The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer. Modern Pathology, 26(1), 71–78.
40. Bass, B. P., Engel, K. B., Greytak, S. R., & Moore, H. M. (2014). A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: How well do you know your FFPE specimen? Archives of Pathology & Laboratory Medicine, 138(11), 1520–1530.
41. Wong, Y. P., Abu Backer, F. M., Tan, G. C., Looi, L. M., Mat Salleh, M. J., A Subramaniam, P. A., Rahimi, R., Ariffin, R., Razali, R. H., Siew, S. F., & colleagues. (2022). Guidelines on retention of pathology records and materials (Version 2/2022). The Malaysian Journal of Pathology, 44(2), 165–176.
42. Rakha, E. A., Pinder, S. E., Bartlett, J. M. S., Ibrahim, M., Starczynski, J., Carder, P. J., Provenzano, E., Hanby, A., Hales, S., Lee, A. H. S., & colleagues. (2015). Updated UK Recommendations for HER2 assessment in breast cancer. Journal of Clinical Pathology, 68(2), 93–99.
43. Yamashita-Kashima, Y., Shu, S., Yorozu, K., Hashizume, K., Moriya, Y., Fujimoto-Ouchi, K., & Harada, N. (2014). Importance of formalin fixing conditions for HER2 testing in gastric cancer: Immunohistochemical staining and fluorescence in situ hybridization. Gastric Cancer, 17(4), 638–647.
44. Ramos-Vara, J. A., Webster, J. D., DuSold, D., & Miller, M. A. (2014). Immunohistochemical evaluation of the effects of paraffin section storage on biomarker stability. Veterinary Pathology, 51(1), 102–109.
45. Zhang, H., Moisini, I., Ajabnoor, R. M., & Turner, B. M. (2020). Applying the new guidelines of HER2 testing in breast cancer. Current Oncology Reports, 22(5), Article 51.
46. Rosa, F. E., Santos, R. M., Rogatto, S. R., & Domingues, M. A. (2013). Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas. Brazilian Journal of Medical and Biological Research, 46(3), 207–216.
47. The Pew Charitable Trusts. (2021). The role of lab-developed tests in the in vitro diagnostics market. https://www.pewtrusts.org/-/media/assets/2021/10/understanding-the-role-of-lab-developed-tests-in-vitro-diagnostics.pdf
48. Congressional Research Service. (2014). Regulation of clinical tests: In vitro diagnostic (IVD) devices, laboratory developed tests (LDTs), and genetic tests. https://sgp.fas.org/crs/misc/R43438.pdf
49. U.S. Food and Drug Administration. (2024). Premarket approval (PMA)—PATHWAY Anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P990081S047
50. U.S. Food and Drug Administration. (2024). Premarket approval (PMA)—Dako HercepTest. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P980018
51. U.S. Food and Drug Administration. (2024). Premarket approval (PMA)—Bond Oracle HER2 IHC System. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P090015
52. U.S. Food and Drug Administration. (2024). Premarket approval (PMA)—InSite Her-2/neu kit. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p040030
53. Furrer, D., Sanschagrin, F., Jacob, S., & Diorio, C. (2015). Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens. American Journal of Clinical Pathology, 144(5), 686–703.
54. U.S. Food and Drug Administration. (2024). PATHWAY Anti-HER-2/Neu (4B5) Rabbit Monoclonal Primary Antibody—P990081/S047. https://www.fda.gov/medical-devices/recently-approved-devices/pathway-anti-her-2neu-4b5-rabbit-monoclonal-primary-antibody-p990081s047
55. Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., & colleagues. (2023). ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Annals of Oncology, 34(8), 645–659.
56. Scott, M., Vandenberghe, M. E., Scorer, P., Boothman, A. M., & Barker, C. (2021). Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay. Journal of Clinical Oncology, 39(15_suppl), 1021.
57. Rüschoff, J., Friedrich, M., Nagelmeier, I., Kirchner, M., Andresen, L. M., Salomon, K., Portier, B., Sredni, S. T., Schildhaus, H. U., Jasani, B., & colleagues. (2022). Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: Correlation with HER2 amplification and HER2 low status. Virchows Archiv, 481(5), 685–694.
58. Nicolò, E., Boscolo Bielo, L., Curigliano, G., & Tarantino, P. (2023). The HER2-low revolution in breast oncology: Steps forward and emerging challenges. Therapeutic Advances in Medical Oncology, 15, Article 17588359231152842.
59. U.S. Food and Drug Administration. (2024). Premarket approval (PMA)—SPOT-LIGHT HER2 CISH KIT. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p050040
60. Dako. (2010). HER2 CISH pharmDxTM Kit. https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100024c.pdf
61. Vysis Inc. (1998). PathVysion HER-2 DNA Probe Kit. https://www.accessdata.fda.gov/cdrh_docs/pdf/P980024S001c.pdf
62. U.S. Food and Drug Administration. (2024). Premarket approval (PMA)—DakoCytomation HER2 FISH pharmDx Kit. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040005
63. U.S. Food and Drug Administration. (2024). Premarket approval (PMA)—VENTANA HER2 Dual ISH DNA Probe Cocktail. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190031S007
64. Olsson, H., Jansson, A., Holmlund, B., & Gunnarsson, C. (2013). Methods for evaluating HER2 status in breast cancer: Comparison of IHC, FISH, and real-time PCR analysis of formalin-fixed paraffin-embedded tissue. Pathology and Laboratory Medicine International, 5, 31–37.
65. Tvrdík, D., Staněk, L., Skálová, H., Dundr, P., Velenská, Z., & Povýšil, C. (2012). Comparison of the IHC, FISH, SISH and qPCR methods for the molecular diagnosis of breast cancer. Molecular Medicine Reports, 6(2), 439–443.
66. Ahn, S., Woo, J. W., Lee, K., & Park, S. Y. (2020). HER2 status in breast cancer: Changes in guidelines and complicating factors for interpretation. Journal of Pathology and Translational Medicine, 54(1), 34–44.
67. Hou, Y., Nitta, H., & Li, Z. (2023). HER2 intratumoral heterogeneity in breast cancer, an evolving concept. Cancers, 15(9), Article 2664.
68. Ohlschlegel, C., Zahel, K., Kradolfer, D., & Hell, M. (2011). HER2 genetic heterogeneity in breast carcinoma. Journal of Clinical Pathology, 64(12), 1112–1116.
69. Vance, G. H., Barry, T. S., Bloom, K. J., Fitzgibbons, P. L., Hicks, D. G., Jenkins, R. B., Persons, D. L., Tubbs, R. R., & Hammond, M. E. (2009). Genetic heterogeneity in HER2 testing in breast cancer: Panel summary and guidelines. Archives of Pathology & Laboratory Medicine, 133(4), 611–612.
70. Liwski, C. R., Castonguay, M. C., Barnes, P. J., Rayson, D., & Bethune, G. C. (2022). HER2 testing in metastatic breast cancer—Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases? Annals of Diagnostic Pathology, 59, Article 151953.
71. Scheel, A. H., Penault-Llorca, F., Hanna, W., Baretton, G., Middel, P., Burchhardt, J., Hofmann, M., Jasani, B., & Rüschoff, J. (2018). Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer. Diagnostic Pathology, 13, Article 19.
72. Koopman, T., Buikema, H. J., Hollema, H., de Bock, G. H., & van der Vegt, B. (2019). What is the added value of digital image analysis of HER2 immunohistochemistry in breast cancer in clinical practice? A study with multiple platforms. Histopathology, 74(6), 917–924.
73. Evans, A. J., Brown, R. W., Bui, M. M., Chlipala, E. A., Lacchetti, C., Milner, D. A., Pantanowitz, L., Parwani, A. V., Reid, K., Riben, M. W., & colleagues. (2022). Validating whole slide imaging systems for diagnostic purposes in pathology. Archives of Pathology & Laboratory Medicine, 146(4), 440–450.
74. College of American Pathologists. (2020). Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. https://documents.cap.org/protocols/cp-breast-biomarker-20-1400.pdf
75. Lim, G. C., Aina, E. N., Cheah, S. K., Ismail, F., Ho, G. F., Tho, L. M., Yip, C. H., Taib, N. A., Chong, K. J., Dharmaratnam, J., & colleagues. (2014). Closing the global cancer divide—performance of breast cancer care services in a middle income developing country. BMC Cancer, 14, Article 212.
76. Lambein, K., Van Bockstal, M., Vandemaele, L., Geenen, S., Rottiers, I., Nuyts, A., Matthys, B., Praet, M., Denys, H., & Libbrecht, L. (2013). Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: Clinical and pathobiological relevance. American Journal of Clinical Pathology, 140(4), 561–566.